中国肿瘤生物治疗杂志2024，Vol.31Issue(8)：815-820,6.DOI:10.3872/j.issn.1007-385x.2024.08.009
DC联合CIK治疗156例局部晚期或晚期胰腺癌的临床疗效
Clinical efficacy of DC combined with CIK in treating locally advanced or advanced pancreatic cancer
摘要
Abstract
Objective:To evaluate the clinical efficacy of dendritic cells(DC)combined with cytokine-induced killer cells(CIK)in the treatment of locally advanced or advanced pancreatic cancer.Methods:A retrospective analysis was conducted on the clinical data of 156 patients with locally advanced or advanced pancreatic cancer who underwent autologous DC combined with CIK treatment in the Oncology Department of the Eastern Theater Command General Hospital from November 2011 to December 2023.Changes in serum tumor markers,lymphocyte subsets,cytokine levels,adverse reactions,short-term efficacy,and long-term efficacy before and after treatment were statistically analyzed.Results:Among the 156 pancreatic cancer patients,92 underwent imaging examinations before and after treatment,with results showing no CR(complete remission),no PR(partial remission),42 cases of SD(stable disease),and 50 cases of PD(progressive disease).The objective remission rate(ORR)was 0%,and the disease control rate(DCR)was 45.65%.There was no significant difference in peripheral blood CA199 levels before and after treatment,but 19 patients showed a reduction of more than 20%after treatment.No statistical differences were observed in CD3+,CD4+,CD8+,CD56+,CD25+peripheral blood lymphocyte subsets levels and CD4+/CD8+T cell ratio before and after treatment(all P>0.05).However,the average levels of IL-2 and IFN-γ in peripheral blood of patients were significantly increased after treatment(all P<0.05),while TNF-α and IL-6 levels showed no significant difference(all P>0.05).The median overall survival(mOS)of the 156 patients was 8.53 months,with 1-year,2-year,and 3-year cumulative survival rates of 39%,15%,and 15%,respectively.No 5-year survival data were available for follow-up.No severe adverse reactions occurred during the treatment.Conclusion:DC-CIK therapy can induce anti-tumor immune responses in patients with locally advanced and advanced pancreatic cancer,achieving certain objective efficacy and potentially prolonging patient survival.关键词
胰腺癌/树突状细胞/细胞因子诱导的杀伤细胞/临床疗效Key words
pancreatic cancer/dendritic cell(DC)/cytokine-induced killer cell(CIK)/clinical efficacy分类
医药卫生引用本文复制引用
舒艳,姚露,傅龚博,雷增杰,贾绍昌,江龙委,周晓娴,何园,张燕,史瑞芳,王竞,汪耔璇,王仲达,朱越,王静..DC联合CIK治疗156例局部晚期或晚期胰腺癌的临床疗效[J].中国肿瘤生物治疗杂志,2024,31(8):815-820,6.基金项目
2022东部战区总医院院管课题(No.22JCYYYB1) （No.22JCYYYB1）
